pathways to a promise

annual report

2003-2004
contents

Letter from the Board Chair  1
Financials  2
Affiliates  5
Research Grants and Awards  8
Cause Partners  18
Board of Directors  22
Our Founder  24
Staff Leadership  24
The Business of Doing Good  25
At the Komen Foundation, we believe in the power of the individual – recognizing the extreme value of one and the dynamic force of many. We are extremely blessed to have so many dynamic volunteers, leaders and partners working beside us in our shared promise to eradicate breast cancer as a life-threatening disease.

And while a scientist at M.D. Anderson might be on a seemingly different course than a volunteer handing out t-shirts at a Komen Race for the Cure® event in DesMoines, or an advocate in Washington D.C., educating members of Congress about breast cancer screening programs, we are all partners in the same promise, the same journey to defeat breast cancer so no woman – or man – will ever know the pain of this disease.

More than two decades ago, Nancy Goodman Brinker initiated this path of hope and discovery in memory of her sister, Susan Goodman Komen, who died of breast cancer at the age of 36. It’s hard to imagine now, but 20 years ago there were no pink ribbons and the disease itself was rarely spoken of in public. There were limited treatment options and certainly no corporate partnerships or federally-funded screening programs. By founding the Susan G. Komen Breast Cancer Foundation, Nancy Brinker blazed a new trail for future generations in the fight against breast cancer.

Throughout our history, we have been driven by this same spirit of discovery – daring to be different, taking risks, looking beyond the horizon, pushing the boundaries of what we know, plunging ahead into the unknown, defying the skeptics and dreaming of new worlds. And that has made all the difference for women across America. Today, a breast cancer diagnosis is no longer a death sentence. In the U.S., fewer women are dying of the disease each year and new drugs and treatments are improving both the quality of patient care and the quality of life for survivors. Hope continues to grow.

Today, a disease that before was never mentioned is now mainstream. And while we have made incredible advances and reached remarkable milestones along the way, we now find ourselves at a fork in the road. Do we stay the course, keeping to our original path? Do we continue to ask the same questions, fund similar research, pursue the same leads? Or, like the pioneers we have always been, do we start down new paths? For us, the choice is clear. We will remain faithful to our heritage – blazing paths in new directions, peering where others dare not look, going where others fear to tread. And in the journey ahead, we will be guided by the wisdom of what we know and the humility of what we don’t. The pathways may change – but the dedication to the original promise remains the same. Thank you for your continued support in helping us make our shared promise to end breast cancer a reality.

LaSalle D. Leffall, Jr., M.D.  
Chair of the Komen Foundation Board of Directors
The Komen Foundation is committed to making a real difference in the lives of all those affected by breast cancer. As part of our commitment, we are extremely careful when it comes to spending the dollars we raise, dedicating as much money as possible to the fight against breast cancer. By relying on a team of volunteers and keeping administrative and fundraising expenses extremely low (11 percent each), in fiscal year 2004 the Foundation was able to invest $98.6 million in grants and programs related to breast cancer research, education, screening and treatment.

### Consolidated Statement of Financial Position

As of March 31, 2004 and 2003

<table>
<thead>
<tr>
<th></th>
<th>2003</th>
<th>2004</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Assets:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and investments</td>
<td>$ 89,296,637</td>
<td>$ 109,792,752</td>
</tr>
<tr>
<td>Receivables</td>
<td>15,417,465</td>
<td>24,248,652</td>
</tr>
<tr>
<td>Net property, plant and equipment</td>
<td>2,704,045</td>
<td>4,350,104</td>
</tr>
<tr>
<td>Other assets</td>
<td>1,884,722</td>
<td>2,072,009</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td><strong>$ 109,302,869</strong></td>
<td><strong>$ 140,463,517</strong></td>
</tr>
</tbody>
</table>

|                |               |               |
| **Liabilities:**|               |               |
| Accounts payable and accrued expenses | $ 4,315,034 | $ 7,354,456 |
| Notes Payable | -             | 1,433,333     |
| Grants payable | 53,970,607   | 75,217,782    |
| **Total Liabilities** | 58,285,641 | **84,005,571** |

<table>
<thead>
<tr>
<th></th>
<th>2003</th>
<th>2004</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Net Assets</strong></td>
<td>51,017,228</td>
<td><strong>56,457,946</strong></td>
</tr>
<tr>
<td><strong>Total Liabilities and Net Assets</strong></td>
<td><strong>$ 109,302,869</strong></td>
<td><strong>$ 140,463,517</strong></td>
</tr>
</tbody>
</table>

### Gross Revenue* vs. Mission Expense

(Dollars in millions)

*Without Value of Contributed Goods and Services
For the fiscal year ending March 31, 2004, the Komen Foundation recognized more than $183 million in cash and in-kind revenues to fight breast cancer, thanks in large part to the hard work of the Affiliate Network and volunteers who helped generate nearly $97 million through the Foundation’s signature series of events, the Komen Race for the Cure®. The Foundation received in-kind gifts (contributed goods and services) including advertising, legal services and Race giveaways like water, bananas and yogurt, that totaled more than $38 million in fiscal year 2004. Because of these donated goods and services, the Foundation was able to spend 75 cents of every dollar raised on research, education, screening and treatment.

### consolidated statement of activities

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Public support and revenue:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contributions</td>
<td>$ 63,871,591</td>
<td>$ 77,231,582</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Komen Race for the Cure®</td>
<td>87,560,401</td>
<td>96,913,909</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other public support and revenue</td>
<td>3,105,282</td>
<td>8,991,270</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total gross revenue</td>
<td>154,537,274</td>
<td>183,136,761</td>
<td>$ 38,289,217</td>
<td>$ 144,847,544</td>
</tr>
<tr>
<td>Less:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Komen Race for the Cure® direct costs</td>
<td>(22,178,356)</td>
<td>(24,340,898)</td>
<td>(11,556,975)</td>
<td>12,783,923</td>
</tr>
<tr>
<td>Net public support and revenue</td>
<td>132,358,918</td>
<td>158,795,863</td>
<td>26,732,242</td>
<td>132,063,621</td>
</tr>
<tr>
<td>Expenses:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program services:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research and awards</td>
<td>28,353,275</td>
<td>39,230,259</td>
<td></td>
<td>39,230,259</td>
</tr>
<tr>
<td>Public health education</td>
<td>46,096,176</td>
<td>44,607,887</td>
<td></td>
<td>33,199,783</td>
</tr>
<tr>
<td>Health screening services</td>
<td>13,967,827</td>
<td>17,438,937</td>
<td></td>
<td>17,438,937</td>
</tr>
<tr>
<td>Treatment services</td>
<td>7,498,601</td>
<td>8,736,906</td>
<td></td>
<td>8,736,906</td>
</tr>
<tr>
<td>Total program services</td>
<td>95,915,879</td>
<td>110,013,989</td>
<td>11,408,104</td>
<td>98,605,885</td>
</tr>
<tr>
<td>Supporting services:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total expenses</td>
<td>33,498,739</td>
<td>43,341,156</td>
<td>14,537,065</td>
<td>28,804,091</td>
</tr>
<tr>
<td>Change in net assets</td>
<td>2,944,300</td>
<td>5,440,718</td>
<td>787,073</td>
<td>4,653,645</td>
</tr>
<tr>
<td>Net assets beginning of year</td>
<td>48,072,928</td>
<td>51,017,228</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net assets end of year</td>
<td>$ 51,017,228</td>
<td>$ 56,457,946</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Where Does Your Dollar Go?

<table>
<thead>
<tr>
<th></th>
<th>2003</th>
<th>2004</th>
</tr>
</thead>
<tbody>
<tr>
<td>75¢ of every dollar raised was spent on mission programs and services.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*KPMG LLP performed the 2003-2004 consolidated audits for the Foundation. Audited financial statements are available upon request.*
Since our beginnings, we have focused our efforts on promising research that will bring us one step closer to eliminating breast cancer as a life-threatening disease. However, research is only one piece of the breast cancer puzzle. One of our top priorities is to reach a diversified audience – including minorities and other groups such as young women, older women, women who partner with women, and the medically underserved – with important breast health and breast cancer information.

To aid in efforts to reach minority populations with culturally appropriate breast health information, the Foundation supports three advisory councils: the African American National Advisory Council, the National Hispanic/Latina Advisory Council and the Asian American/Pacific Islander National Advisory Council. Their mission is to provide guidance and direction on programs designed to reduce the disparities in mortality of breast cancer among their respective communities. In addition, the Foundation produces a variety of age appropriate and culturally sensitive breast health and breast cancer education materials in more than 10 languages.

The Foundation also serves as an educational resource for various audiences, including the general public, Komen Affiliates and staff, health care providers, corporate partners and congressional leaders. Education and outreach are accomplished through newsletters, conferences, advertising, trainings, print and audio visual education materials and partnerships. The Foundation’s award-winning Web site, www.komen.org, is one of the most comprehensive breast cancer resources online today. The site offers an online breast self-examination instruction tool and up-to-the-minute information about research findings, local outreach initiatives, volunteer opportunities, events and Komen Foundation programs and partners. The Foundation also operates a National Toll-Free Breast Care Helpline, 1.800 I'M AWARE®, that is answered by a trained and caring staff and volunteers.
The Komen Foundation’s Affiliate Network is located in 48 states and serves more than 1,700 counties in the United States, and three foreign countries, including Germany, Italy and Puerto Rico.

At the Komen Foundation, the funds we raise are only as good as our ability to make a real impact where it affects us most – in our local hometowns and communities. That’s why up to 75 percent of the net proceeds raised at local fundraising events like the Komen Race for the Cure® remain in the community where it’s raised. The remaining 25 percent funds the Foundation’s Award and Research Grant Program.

At the heart of our local initiatives are more than 75,000 volunteers and community leaders working tirelessly to raise awareness and much-needed dollars for the fight against breast cancer. Komen Affiliates fund community-based programs that address health disparities and provide education, screening and treatment services for the medically underserved and other targeted populations such as minorities, lesbians/women who partner with women, the homeless, immigrants, low-income women, young women and those living in rural areas. A large portion of the dollars granted at the Affiliate level are used to help reduce or eliminate barriers to care such as language, cultural differences, transportation, lack of insurance and childcare.

As a rule, Komen Affiliates fund programs and services that are non-duplicative – meaning the service or program would not exist without Komen funding. Based on a detailed community profile, Komen Affiliates identify these gaps and work to fill them. And they don’t work alone. Many initiatives are collaborations with providers of breast health services like the YWCA and the American Cancer Society – the top two organizations funded by Komen Affiliates.
Through the dedicated efforts of volunteers, Komen Affiliates are able to fund much-needed breast cancer education, screening and treatment programs, as well as provide clinical trials support, in the population categories outlined below. Examples of some of the innovative programs funded within these population groups are detailed on page 7.

**population categories**

**Breast Cancer Patients or Persons at High Risk**
- Advanced Breast Cancer Patients
- Breast Cancer Patients
- Breast Cancer Survivors
- High-Risk Persons
- Lymphedema
- Recently Diagnosed

**Health Professionals, Public and Other**
- Clinical Trials
- Community
- Health Educators
- Healthcare Providers
- Scientists

**Medically Underserved**
- Homeless
- Immigrants
- In a Shelter/Clinic
- Low-Income
- Migrant Workers
- Refugees
- Rural
- Uninsured/Underinsured

**Race and Ethnicity**
- African-American
- Asian/Pacific Islander
- East Indian
- Hispanic/Latino
- Middle Eastern
- Native-American

**Other**
- Breast Cancer Family Members
- College Students
- High School Students
- Incarcerated
- Lesbian
- Low-Literacy
- Minorities
- Persons with Disabilities

**screening, treatment and education grants by population category**

Grant programs may be counted in more than one area based upon multiple populations served.

**affiliate mission dollars**

![Graph showing funding trends from 1998 to 2004 for Education and Outreach, Screening, and Treatment](image-url)
Below are several examples of the innovative programs and services in the areas of education, screening and treatment funded locally by Komen Affiliates.

**Affiliate:** Komen Peoria Memorial Affiliate  
**Grantee:** Hult Health Education Center  
**Grant Title:** Breast Cancer Awareness Program

The Hult Health Education Center has developed a program that educates high school and college age females about breast health and breast cancer, including breast anatomy and physiology, normal and fibrocystic tissue and changes, breast cancer risk factors, signs and symptoms of the disease and the overall importance of early breast cancer detection through breast self-exam. By reaching women as teens and young adults, they will hopefully begin a lifetime of good breast health practices.

**Affiliate:** Komen Orange County Affiliate  
**Grantee:** YWCA EncorePlus  
**Grant Title:** YWCA EncorePlus

Since 1993, the YWCA EncorePlus program of Orange County has provided more than 23,000 underserved women age 40-64 of diverse ethnic backgrounds with free mammograms, clinical breast exams, breast self-exam instruction and overall breast health information in their own language in their own communities. Screenings are offered in a variety of neighborhoods in convenient locations such as senior centers, community centers, churches and clinics. This mobile program provides equal access to not only quality breast health screening and education, but also life-saving follow-up and diagnostic and treatment services for women throughout Orange County.

**Affiliate:** Komen Denver Affiliate  
**Grantee:** Colorado Cancer Research Program (CCRP)  
**Grant Title:** Enhancing Clinical Trials Participation in a Community-Based Setting

The intent of this grant is to enhance physician participation in clinical trials by providing the support resources necessary for enrollment of individuals in breast cancer clinical trials. While breast cancer patients comprise the highest percentage of CCRP’s clinical trial participation, the overall participation in treatment, cancer control or preventative trials remains less than 10 percent of eligible women. Physician participation in CCRP-offered clinical trials is a key component for overall patient clinical trials participation. As such, CCRP is focusing on physician education and support to enhance overall breast cancer clinical trials participation.

**Affiliate:** Komen Greater New York City Affiliate  
**Grantee:** Columbia University at Harlem  
**Grant Title:** Patient Navigator Program

This project is an offshoot of a program initiated in 1990 by Cancer Control Center of Harlem at Harlem Hospital Center to address the disparities in breast cancer survival that exist between poor African American and Latina women living in central Harlem and African American and Caucasian women living in other parts of the United States. The Patient Navigator Program is designed to ensure that any woman with a suspicious finding during a breast screening receives a timely diagnosis and treatment. The Patient Navigator accomplishes this through one-on-one contact with the patient. Funding supports two Patient Navigators who aim to educate 9,000 women and provide navigation services related to screening to 2,000 women and provide navigation services related to treatment to 150 women.

**Affiliate:** Komen Maryland Affiliate  
**Grantee:** Baltimore County Department of Health  
**Grant Title:** Breast Cancer Screening, Diagnosis, Treatment, Case Management

This program provides Hispanic, Korean and African American women in the Baltimore area with breast cancer screening, diagnosis and treatment services. Hispanic and Korean outreach workers provide culturally appropriate intervention during this process and help interpret as needed. If a cancer diagnosis is made, an outreach worker will continue to work with the patient as an interpreter and an advocate throughout the treatment process. Public health nurses provide case management for women with abnormal screening results. Case management continues during the diagnostic process, as well as during treatment. In addition, Hispanic office support by a bilingual office assistant is available for Latinas seeking or receiving breast cancer screening, diagnosis and/or treatment.

**Affiliate:** Komen Arkansas Affiliate  
**Grantee:** Hope, Inc.  
**Grant Title:** Patient Assistance Program

Hope, Inc. provides breast cancer patients who are uninsured or underinsured with prescription drug programs and direct financial assistance. If a breast cancer patient suffers a loss of income due to her cancer treatment, she may also be eligible to receive emergency financial assistance.
The Komen Foundation funds awards and research projects at leading institutions around the globe. Combined with the funding of community outreach programs that provide much-needed education, screening and treatment services for the medically underserved, the Komen Foundation is diligently working to not only find a cure for breast cancer – but to also discover its causes and methods of prevention so that one day breast cancer is completely eliminated from our world. It will require both research and community outreach to reach our ultimate goal – but as your partner in this fight, we will pursue every pathway to the promise to end breast cancer as a life-threatening disease.

**Research Grants and Awards**

The areas of interest in the basic, clinical and translational research grant program include basic science, clinical studies for improved treatments, translational research, complementary and integrated medicine, diagnostic methods, environmental factors, genetic epidemiology, diet and nutrition, psychosocial support, prevention, survivorship research and other imaging techniques/studies.

### Biology of Breast Cancer

**Characterizing Determinants of Tamoxifen Resistance in Human Breast Cancer: Role of CtIP (RBBP8)**

C. Marcelo Aldaz, Ph.D.
University of Texas M.D. Anderson Cancer Center

**Stromal Caveolin-1 Regulation of Breast Cancer Growth and Metastasis.**

Robin Anderson, Ph.D.
Peter MacCallum Cancer Centre

**Epigenetic Consequences of BRCA1: The Key to its Role as a Tumor Suppressor Gene in Human Breast Cancer**

Bradley Arrick, M.D.
Trustees of Dartmouth College

**Mouse Models of Breast Cancer Based on Epigenetic Silencing of the Hic-1 and AP-2α/β Genes**

Stephen Baylin, M.D.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

**Epithelial Dependence on the Vasculature**

Laura Benjamin, Ph.D.
Beth Israel Deaconess Medical Center

**BP1, a New Homeobox Gene: a Strong Potential Target for Therapy of Breast Cancer**

Patricia Berg, Ph.D.
George Washington University Medical Center

- Although more and more is known about the genes involved in breast cancer, better targets for therapy are still needed. Dr. Berg and her team are studying a gene called BP1 as a potential target for breast cancer therapy. BP1 is “turned on” or active in 100% of women whose breast cancer has the poorest prognosis. In fact, BP1 is active in 80% of breast tumors overall. BP1 expression also exhibits a racial disparity: 89% of the tumors of African American women are BP1 positive, compared with 57% of the tumors of caucasian women. It is known that African American women with breast cancer are more likely to die than caucasian women with breast cancer, but the reason for this is unknown. If BP1 could be used as a target for the treatment of African American women with breast cancer, this may increase their survival.

What is the significance of BP1 activation in breast cancer? A clue comes from the fact that when BP1 activity was prevented in leukemia cells (where BP1 is also active), the cells died, suggesting that BP1 expression was necessary for cancer cell survival. If true for breast cancer cells, this would suggest a therapy for BP1 positive tumors: turn off the BP1 gene, thereby killing the malignant cells. Few normal cells have activated BP1, so this treatment would be quite specific for tumor cells.

The main goal of this research is to determine the possible usefulness of BP1 as a molecular target by proving its role in the survival of breast cancer cells. The scientists hope to discover whether turning off BP1 will kill those cells and determine whether enhanced BP1 activity (like that seen in breast tumors) inhibits the ability of a chemotherapeutic drug to kill breast cancer cells. In turn, reducing BP1 levels might allow the use of a lower strength of drug to treat patients. Using microarray technology, the researchers will measure the effect of BP1 activation on changes in activation or repression of other genes associated with cell survival and resistance to cell death, as well as genes important in cell growth. Overall, these studies will establish the potential of BP1 as a molecular target for treatment of breast cancer.

**Role of the Heparin-Binding Growth Factor, Pleiotrophin, in Breast Cancer Motility and Invasion**

Emma Bowden, Ph.D.
Georgetown University

**Ceramide Metabolism As Prognostic Marker Of Chemotherapy Responsiveness And Metastatic Potential In Breast Cancer**

Myles Cabot, Ph.D.
John Wayne Cancer Institute

**CBFA2T3 is a Novel Breast Cancer Tumour Suppressor Gene: Investigation as a Prognostic Marker and Development of Drug Targets**

David Callen, Ph.D.
University of Adelaide

**Preclinical Models for Treatment of Residual Neoplastic Disease**

Lewis Chodosh, M.D.
University of Pennsylvania School of Medicine

**Progesterone Receptors and Hormonal Prevention of Breast Cancer**

Orla Conneely, Ph.D.
Baylor College of Medicine

**Fibroblast Activation Protein-Alpha Activation of a Bacterial Toxin as Targeted “Anti-Stromal” Therapy for Breast Cancer**

Samuel Denmeade, M.D.
The Johns Hopkins School of Medicine
Genes ultimately drive cells to make proteins that can contribute to the metastatic process when they are abnormally expressed. At present, the metastatic potential of a breast cancer is estimated, to a large extent, by its pathologic features including spread to axillary lymph nodes. Lymph node status is the main factor used to classify women into treatment regimens beyond that of surgical excision of their tumor (adjuvant therapy). Adjuvant therapy consists of using drugs to reach any cancer cells that may have escaped from the primary tumor. It is costly and may cause highly toxic side effects. Up to 70% of patients who would have been cured by surgery alone receive this treatment needlessly, just in case there is undetected tumor spread. Studies that can detect predictive changes at the level of the gene (DNA) that determine whether a cancer will spread (metastasize) or, more importantly, will not metastasize.

Dr. Geradts and his team pioneered a new technology called array based comparative genomic hybridization (aCGH). This technology can examine DNA from tumor cells for differences in the genetic material compared to DNA from normal cells. Preliminary studies have indicated that this technology can be used to better define the aggressiveness of a tumor. Dr. Geradts and his team hypothesize that aCGH technology can be employed to discover metastasis suppressing and promoting genes in small breast cancers. These genes can then be used to more accurately classify breast cancer patients into appropriate adjuvant treatment groups. This classification process would ideally eliminate the application of adjuvant therapy to patients who do not require it.

Ultimately, this tool should help clinicians to eliminate overtreatment of small breast cancers, which would benefit tens of thousands of women. It will also help scientists to discover new prognostic and predictive markers, in addition to novel therapeutic targets. Finally, it will further understanding of the events leading to the spread of breast cancer cells.
Disruption of Breast Cancer Chemoresistance by the Translational Antagonist 4E-BP1: A Bitransgenic Mouse Model
Vitaly Polunovsky, Ph.D.
University of Minnesota

Earlier Detection of Primary and Recurrent Breast Cancer Using Autoantibodies
John Robertson, M.D.
The University of Nottingham

A Murine Model of Breast Cancer-Associated Lymphedema: Genome-Wide Transcriptional Profiling for the Study of Lymphedema Pathobiology, Cellular Signaling Mechanisms and Mechanisms of Therapeutic Lymphangiogenesis
Stanley Rockson, M.D.
Stanford University School of Medicine

Role of Progestins and Progesterone Receptors in Hormone-Dependent Human Breast Cancers
Carol Sartorius, Ph.D.
University of Colorado Health Sciences Center

Determining the Role of CD44 in Breast Cancer Metastasis To the Lung
Joyce Schroeder, Ph.D.
University of Arizona

BRMS1 Regulates Osteopontin Expression in Metastatic Breast Cancer
Lalita Shevde-Samant, Ph.D.
University of South Alabama

Biology of Breast Cancer Candidate Gene Analysis: The Direct Approach to Identification of Additional Breast Cancer Susceptibility Genes
Csilla Szabo, Ph.D.
International Agency for Research on Cancer

Directed Delivery of RNA Interference Strategies to Breast Malignancies
Ernest Terwilliger, Ph.D.
Beth Israel Deaconess Medical Center

The Cellular Basis of Pregnancy-Mediated Protection Against Breast Cancer
Kay-Uwe Wagner, Ph.D.
University of Nebraska Medical Center

Molecular Mechanism of Estrogen Antagonists induced Suppression of Breast Cancer
Sheng Wang, Ph.D.
Boston University School of Medicine

Origins of Mammary Tumor Stromal Cells
Robert Weinberg, Ph.D.
Whitehead Institute for Biomedical Research

Role of Retinoid X Receptor and its Ligand in Breast Cancer
Xiao-kun Zhang, Ph.D.
The Burnham Institute

Early Detection, Diagnosis and Prognosis
Nipple Aspirate Fluid Basic Fibroblast Growth Factor
Mai Nguyen Brooks, M.D.
The Regents of the University of California

JAB1-Mediated p27Kip1 Degradation as a Prognostic Factor and a Therapeutics Target for Breast Cancer
Francois Claret, Ph.D.
M.D. Anderson Cancer Center

She Signaling Proteins: Prognostic and Predictive Markers in Breast Cancer
A. Raymond Frackelton, Ph.D.
Roger Williams Hospital

Clinical Utility of Hypermethylated Genes in Primary Tumors and Body Fluids as Prognostic Markers of Breast Cancer Patients
Dave Hoon, Ph.D.
John Wayne Cancer Institute

Phosphopeptide Antibodies as Prognostic Indicators for Breast Cancer
Andrew Laudano, Ph.D.
University of New Hampshire

DNA Methylation Profiles for Diagnosis, Monitoring and Residual Disease Detection in Breast Cancer
Victor Levenson, M.D.
Northwestern University, Feinberg School of Medicine

Prediction of Breast Cancer Outcome to Adjuvant Chemotherapy Using Expression Profiling
Dennis Sgroi, M.D.
Massachusetts General Hospital

Computed Tomographic Prediction of Response to Treatment in Breast Cancer Induced Bone Metastasis
Brian Snyder, M.D.
Orthopedic Biomechanics Laboratory

Etiology (Origins and Causes)
Genetic Basis of DNA Repair Deficiency in Sporadic Breast Cancer
Stephen Grant, Ph.D.
University of Pittsburgh

Role of Nitrites/Nitrates in the Etiology of Breast Cancer
Mary Beth Martin, Ph.D.
Georgetown University

Characterization of Immunosuppressive Properties Induced by Eukaryotic Vector-Mediated Expression of HERV Genes Derived from Human Breast Cancer Cells
Feng Wang-Johanning, M.D.
UT M.D. Anderson Cancer Center

Prevention
Molecular Targets of Breast Cancer Prevention by n-3 PUFAs
Huseyn Aktas, DVM
Harvard Medical School

Role of Aromatase and COX-2 Inhibition in the Prevention of p53-Mediated Breast Cancer
Richard Arenas, M.D.
Baystate Medical Center

A Novel Combinatorial Approach to Inhibit the Development of Mammary Cancer
Sarma Dittakavi, Ph.D.
University of Toronto

Anticancer and Chemopreventive Potential of Constituents of Black Cohosh on Breast Cancer
Linda Emhond, Ph.D.
Columbia University College of Physicians and Surgeons

Type-I and Type-II Anti-Tumor-Promotion Agents: Combinations of Tamoxifen, a New Retinoid, and Moderate Dietary Restriction in the Prevention of Experimental Breast Cancers
Isao Eto, Ph.D.
University of Alabama at Birmingham
Lipoprotein/Annexin I as a Unique Target of Mechanism-Based Chemoprevention of Breast Cancer
Fusao Hirata, M.D.
Wayne State University

Inhibition of the Breast Cancer Marker MUC1 by the Chemopreventative, Indole-3-Carbinol
Insong Lee, Ph.D.
University of Maryland

Optical Transillumination Spectroscopy For Monitoring Breast Cancer Risk Changes
Lothar Lilge, Ph.D.
University Health Network

Delivery of Recombinant Mucin 1 (MUC1) Protein and MUC1 Cytotoxic T Cell Epitopes into the Cytoplasm of Antigen Presenting Cells Using a Membrane Permeable Peptide for the Immunotherapy of Breast Cancer
Geoffrey Pietersz, Ph.D.
The Austin Research Institute

Does RARbeta2 P2 Methylation Predict Short-Term Breast Cancer Risk?
Victoria Seewaldt, M.D.
Duke University

Monitoring the Effectiveness of NSAIDs Chemoprevention in Breast Cancer Using the CD13/APN Cell Surface Peptidase
Linda Shapiro, Ph.D.
University of Connecticut Health Center

Targeting DNA polymerase β and Base Excision Repair in Breast Cancer: Characterization of a Novel p53-Independent Anti-Tumor Response
Robert Sobol, Ph.D.
University of Pittsburgh Cancer Institute

Green Tea Intervention for Weight Gain Prevention among Women with Breast Cancer
Cynthia Thomson, Ph.D.
University of Arizona

Effects of Soy on Estrogen Insufficiency-induced Tamoxifen-Nonresponsive Breast Cancer
Jin-Rong Zhou, Ph.D.
Beth Israel Deaconess Medical Center

Treatment
A Novel Combination Approach of Anti-Her2/Neu and Anti-Prolactin for Breast Cancer
Wen Chen, Ph.D.
Clemson University

Genomic Consequences of Restoring p53 Transactivating Function with PRIMA-1 in Breast Cancer
Sayed Daoud, Ph.D.
Washington State University

Comparing a Plant Based Olive Oil Diet to a Conventional Diet in Women Diagnosed with Invasive Breast Cancer After the Age of 50 for Improvement in Biomarkers and Weight Loss
Mary Flynn, Ph.D.
The Miriam Hospital

Radiosurgical Irradiation of the Tumor Bed for Early Stage Breast Cancers
Lijun Ma, Ph.D.
University of Maryland School of Medicine

A Novel Antiangiogenic and Antimetastatic Agent for Breast Cancer
Francis Markland, Ph.D.
USC Keck School of Medicine

Novel Breast Cancer Therapeutic Vectors Based on a Paramyxovirus Fusion Protein
Griffith Parks, Ph.D.
Wake Forest University Health Sciences

Inhibition of Breast Cancer Growth by a Novel Regulator of EGFR
Arun Rishi, Ph.D.
Karmanos Cancer Institute, Wayne State University

Immunogene Therapy of Breast Cancer
Mark Smyth, Ph.D.
The University of Melbourne

Overcoming Apoptosis-Resistance by Bcl-2/Bcl-xL-Bispecific Small Molecule Inhibitors as a Novel and Molecular Targeted Therapy for Breast Cancer
Liang Xu, M.D.
University of Michigan Medical School

Development of a Conditionally Replicative Adenovirus Targeted to HER-2/Neu-overexpressing Breast Cancer Through an Antisense Iron-responsive Element
Duem-Hwa Yan, Ph.D.
M. D. Anderson Cancer Center

postdoctoral fellowships

The Komen Foundation funds individuals engaged in academic study beyond the level of a doctoral degree in the areas of breast cancer research, public health or epidemiology.

Biology of Breast Cancer
Understanding Telomere Dynamics in Breast Cancer
Steven Artandi, M.D.
Stanford University

Using Mouse Models to Define the Pathway of P53-Mediated Tumor Suppression in Breast Cancer
Laura Attardi, Ph.D.
Stanford University

INT6 is a Potential Breast Tumor Suppressor Gene that Regulates the Proteasome
Eric Chang, Ph.D.
Baylor College of Medicine

Role of Jun Activation Domain-Binding Protein (JAB1) in Breast Tumorigenesis
Francois Claret, Ph.D.
The University of Texas M.D. Anderson Cancer Center

Wrch1: A Novel Rho GTPase in Breast Cancer Development
Channing Der, Ph.D.
University of North Carolina at Chapel Hill

A Novel Strategy for the Identification of Tumor Suppressors in Human Breast Cancer
Stephen Elledge, Ph.D.
Harvard Partners Center for Genetics and Genomics

The Role of BRCA1 in Development and Maintenance of Genomic Integrity in the Terminal End Bud
Priscilla Furth, M.D.
Georgetown University, Lombardi Cancer Center
Regulation of PEA-15 During Breast Cancer Oncogenesis
Mark Ginsberg, M.D.
The Scripps Research Institute

Characterization of Mcs7, an Inherited Mammary Carcinoma Susceptibility Locus on Rat Chromosome 10
Michael Gould, Ph.D.
University of Wisconsin-Madison

Functional and Structural Interactions Between Rad51, Rad54, and Brca2 Proteins During Recombinational DNA Repair of DNA Double-Stranded Breaks
Wolf-Dietrich Heyer, Ph.D.
University of California, Davis

Molecular Mechanisms of Fas-Mediated Cell Death Induced by Tumor-Specific Ether Lyso phospholipid Derivatives
Anne-Odile Hueber, Ph.D.
Institute of Signaling, Developmental Biology, and Cancer

Molecular Mechanisms of LRH-1 Function in Breast Tissue
Holly Ingraham, Ph.D.
University of California, San Francisco

DNA Methylation of SLIT-2 as a New Marker for the Early Diagnosis and the Use of Soluble SLIT-2 as a New Therapeutic for Breast Cancer
John Minna, M.D.
UT Southwestern Medical Center

The Proteome of Delta Protein Kinase C in Breast Cancer
Daria Mochly-Rosen, Ph.D.
Stanford University School of Medicine

Role of Gab2 in Breast Cancer
Benjamin Neel, Ph.D.
Beth Israel Deaconess Medical Center, Harvard Medical School

E2F Transcription Factors in Mammary Gland Development and Tumorigenesis
Joseph Nevins, Ph.D.
Duke University

Regulation of Genomic Stability Through Cell Cycle Checkpoint Signaling
Matthew O’Connell, Ph.D.
Mount Sinai School of Medicine

Defining the Role of a Novel CDK-Related Kinase in Cell Cycle Progression
Patrick O’Farrell, Ph.D.
University of California, San Francisco

Centrosome Replication and the Role of BRCA1 in Breast Cancer
Jeffrey Parvin, M.D.
Brigham and Women’s Hospital

The Role of CXCL12 and CXCL14 Chemokines in the Regulation of Breast Cancer Cell Growth and Invasion
Kornelia Polyak, M.D.
Dana-Farber Cancer Institute

The Role of CKS Proteins in Cell Cycle Control and Breast Cancer
Steven Reed, Ph.D.
The Scripps Research Institute

Role of Novel Sulfatases in Breast Cancer
Steven Rosen, Ph.D.
University of California San Francisco

Mechanism for BRCA1 Regulation of Genomic Stability
Eliot Rosen, M.D.
Georgetown University

Characterization and Targeting of Cell Surface Expressed Nucleolin in Breast Cancer Angiogenesis
Erkki Ruoslahti, M.D.
The Burnham Institute

Functional Significance of HtrA1 Downregulation in Breast Cancer: Implications for Platinum Resistance
Viji Shridhar, Ph.D.
The Mayo Clinic Rochester

The Role of Estrogen Receptor Coactivators in Tamoxifen Resistance
Carolyn Smith, Ph.D.
Baylor College of Medicine

Functional Roles of HOXB7 in Tumorigenesis and Metastasis of Mammary Carcinoma
Saraswati Sukumar, Ph.D.
Johns Hopkins University School of Medicine

Riboflavin Trafficking in Breast Cancer
Peter Swaan, Ph.D.
University of Maryland

The Role of TP53 Mutation in Genome Stability and Chemotherapeutic Resistance in Breast Cancer
Barbara Weber, M.D.
University of Pennsylvania

Vitamin D3 and Wnt/B-catenin Signaling in Mammary Cells
JoEllen Welsh, Ph.D.
University of Notre Dame

Characterization of the Tumor Suppressor RASSF1A in Breast Cancer Initiation and Progression
Michael White, Ph.D.
University of Texas Southwestern Medical Center at Dallas

Early Detection, Diagnosis and Prognosis
ErbB receptors and resistance to aromatase inhibitors in breast cancer
Carlos Arteaga, M.D.
Vanderbilt University Medical Center

Measurement of the X-Ray Attenuation Coefficients of Breast Tissues and Tumors Using Digital Tomosynthesis
Daniel Kopolans, M.D.
Massachusetts General Hospital

Etiology (Origins and Causes)
Molecular Epidemiology of Secondary Lung Cancer in Breast Cancer Patients
Peter Shields, M.D.
Georgetown University

Treatment
Mechanisms of Responses of Cancer Cells to Mutant-Template Telomerase RNA
Elizabeth Blackburn, Ph.D.
The Regents of the University of California
Use of Hypoxia- and Radiation-activated Cre/loxP Switch Vectors for Gene Therapy of Breast Cancer
Michael Joiner, Ph.D.
Wayne State University

Mechanistic Synergy of HDAC and Topo II Inhibitors
Pamela Munster, M.D.
H. Lee Moffitt Cancer Center and Research Institute

NB2 a Novel Antitumor Agent for Breast Cancer: Implication of Proteomics in Target Identification
Nouri Neamati, Ph.D.
University of Southern California

In an effort to design compounds with new mechanisms of action, Dr. Neamati and team have recently identified a novel small molecule drug called NB2 that shows remarkable potency against a panel of human tumor cell types including breast, prostate and ovarian cancers. Through prior testing, the effectiveness of NB2 in prostate cancer has already been confirmed. However, it was recently observed that NB2 is 16 to 90 times more potent against breast cancer cells in laboratory testing. The immediate goal of the present study is to identify the cellular target(s) and how NB2 will be used to kill breast cancer cells.

In this study, the scientists use proteomics technologies (the study of cellular proteins) to identify the target(s) of NB2. Proteomics has been used to discover new markers for diagnosis and to understand the molecular basis leading to the initiation and progression of breast tumors. The effectiveness and toxicity level of NB2 will also be evaluated. The study’s long-term objective is to conduct human clinical trials with NB2. The expected outcome of the present study is to demonstrate that NB2 is a highly potent new investigational compound effective for breast cancer. The scientists will demonstrate the ability of proteomic approaches to identify the molecular drug target and the mechanisms involved in the antitumor activity of new anticancer drugs like NB2. The preclinical evaluations will provide the basis for the design of future clinical trials in humans. If successful, this preclinical study will expedite efforts in developing NB2 as a potential drug for breast cancer patients.

The Role of Growth Factors/Stress Signaling Pathways in Developing Endocrine Resistance of Breast Cancer
Kent Osborne, M.D.
Breast Center, Baylor College of Medicine

Structure-Based Inhibitor Design for a Cancer Target in De Novo Purine Biosynthesis Pathway
Ian Wilson, Ph.D.
The Scripps Research Institute

In this study, the scientists will demonstrate that NB2 is a highly potent new investigational compound effective for breast cancer. The scientists will demonstrate the ability of proteomic approaches to identify the molecular drug target and the mechanisms involved in the antitumor activity of new anticancer drugs like NB2. The preclinical evaluations will provide the basis for the design of future clinical trials in humans. If successful, this preclinical study will expedite efforts in developing NB2 as a potential drug for breast cancer patients.

population specific research

The population specific research program involves innovative research projects focusing on the epidemiology of breast cancer within specific populations at risk for the disease. The focus of the program is to identify unique needs, trends and barriers to breast health care among specific populations such as African American, Native Hawaiian and Pacific Islanders, Asian American, Hispanic/Latino, Native American, Lesbian, Low Literacy, Breast Cancer Survivors, Women with Disabilities and other defined communities.

Cancer Control, Survivorship and Outcomes
Predicting Memory Problems in Breast Cancer Survivors
Kris Kaemin, Ph.D.
University of Arizona

The Re-entry of Hispanic Breast Cancer Survivors to the Healthcare Delivery System and Workforce
Betsy Risendal, Ph.D.
University of Colorado Health Sciences Center

The information collected on diagnosis, treatment and outcomes in this study provided a much more accurate and detailed picture of these two special groups of women than in previous single hospital-based studies. The purpose of this study is to further explore the relationship between breast cancer and pregnancy. Three themes are being used to do this:

- Theme 1 investigates the management and outcomes of gestational breast cancer and breast cancer in young women who subsequently conceive and will look at how the management and outcomes of these women differ from all other women in Western Australia diagnosed with breast cancer before the age of 45.
- Theme 2 reviews the role of imaging and pathology in women diagnosed with gestational breast cancer. Their imaging and pathology is being compared with those of non-gestational breast cancers diagnosed in similarly aged women. This comparison will
allow scientists to assess what effect pregnancy and breastfeeding has on the imaging and pathology of breast cancers, and how this may affect the diagnosis, treatment and outcomes of gestational breast cancer.

- Theme 3 investigates the psychosocial needs of women diagnosed with gestational breast cancer. This involves interviewing and listening to how women themselves are affected by the disease. No prior study of gestational breast cancer has reported from the women’s point of view. This study will provide a new insight into how pregnancy and breastfeeding may affect breast cancer diagnosis, treatment and outcomes.

The information from this study will assist in the development of best practice guidelines that health professionals can use when managing this group of special women. It will also enable women diagnosed with gestational breast cancer and those younger women diagnosed with breast cancer who may want to have children in the future, to make informed choices about the management of their breast cancer and pregnancy.

Beyond Survival: Assessing and Addressing the Needs of Breast Cancer Survivors Suffering from Post-Treatment Symptomology
Saska Subramanian, Ph.D.
University of California, Los Angeles

Does Adjuvant Breast Therapy Change Bone Mineral Density in Postmenopausal Women?
Catherine Van Poznak, M.D.
Memorial Sloan-Kettering Cancer Center

Early Detection, Diagnosis and Prognosis
Field Trial of Mobile Digital Telemammography – Phase II
Joseph Gitlin, DPH
Indian Health Service

Asian Indian Breast Cancer Project
Hee-Soon Juon, Ph.D.
Johns Hopkins Bloomberg School of Public Health

Etiology
Identification and Characterization of Patients at Risk for Hereditary Breast Cancer in Southern Brazil
Patricia Ashton-Prolla, M.D.,Ph.D.
Fundacao Medica do Rio Grande do Sul

Racial Differences in Early Onset Breast Cancer
Bruce Haffty, M.D.
Yale University

A Tumor-Based Analysis of Uncharacterized DNA Variants in BRCA1/2 Focusing on Undertested Populations
Paul Marcom, M.D.
Duke University Medical Center

Protein Profiling for the Identification of Serum Biomarkers for Early Detection and Prevention of Breast Cancer in African American Women
Padma Uppala-Tadi, Ph.D.
Loma Linda University

Prevention
Assessing Barriers to Mammography: Reducing Disparities for Women with Disabilities
Judith Barr, ScD
Connecticut Peer Review Organization, Inc, dba Qualidigm

Can a Faith-Based Participatory Intervention Study Increase Breast Health Care Participation in African American Women?: A Randomized Comparison
Janice Bowie, Ph.D.
Johns Hopkins University Bloomberg School of Public Health

An Innovative Approach to Increasing Early Detection of Breast Cancer within Tribal Communities
Connie Garcia, MA
Albuquerque Area Indian Health Board, Inc.

Community-Based Participatory Health Research: Understanding the Cultural Assets of Southeast Asian Women for the Promotion of Breast Health
Franklin Kim, Ph.D.
Asian Pacific Development Center

Increasing Repeat Mammography Screening Among Low-Income Filipina-American Women
Annette Maxwell, Ph.D.
University of California, Los Angeles

Determining The Impact of Health System Navigation Skills of Asian Americans on Breast Cancer Screening
Nadereh Pourat, Ph.D.
University of Southern California

American Indian Breast Cancer Prevention: Turning Knowledge into Action
Delight Satter, MPH
University of California, Los Angeles

imaging technology

Imaging technology grants focus on research that could lead to improved breast cancer screening and diagnosis.

Biology of Breast Cancer
Application of Molecular Imaging to Breast Cancer: Imaging of CRIP1, a Gene Overexpressed in 90% of Human Breast Cancers
James Basilion, Ph.D.
Mass General Hospital, Harvard Medical School

Clinical Imaging of Breast Cancer Hypoxia and Response to Therapy
Debasish (Debu) Tripathy, M.D.
University of Texas Southwestern Medical Center

Early Detection, Diagnosis and Prognosis
Fluorescent Imaging To Delineate Margins In Breast Conservative Surgery Using Green Fluorescent Protein Expressing Oncolytic Herpes Virus
Yuman Fong, M.D.
Memorial Sloan-Kettering Cancer Center

Improving Specificity of Breast Cancer Diagnosis with Proton MRIS
Jiani Hu, Ph.D.
Wayne State University

- Magnetic Resonance Imaging (MRI) of the breasts, which uses radio waves and magnets rather than x-rays, identifies abnormalities by their appearance and their response to an
Magnetic resonance spectroscopy (MRS) uses the same equipment but looks at tissue metabolism. This provides independent information about tumor biochemistry. Distinctive metabolites have been observed in breast cancer, allowing better discrimination between cancer and benign lesions. Biopsy could be avoided if a lesion were clearly benign. However, current technology has precluded applying MRS to small lesions – the very lesions that may be detected only by MRI and, if cancerous, have the best chance of cure.

Through his study, Dr. Hu proposes the development and testing of a high resolution multi-voxel MRS technique (MRSI) capable of evaluating small lesions, both in the setting of initial diagnosis and in detection of residual or recurrent tumor following therapy. If successful, this approach will not only avoid many “unnecessary” biopsies, but will also provide guidance to optimal patient management and thus improve outcomes.

If successful, the research will also develop MRS methods that improve early detection and treatment monitoring of breast cancer. It might also allow easy comparison between cancerous and normal breast tissue in an individual patient thereby improving detection of new/additional lesions. It will also provide a robust and practical technique that is simple to operate and applicable on any imager capable of MRS. This would allow MRS of the breast to be performed whenever a breast MRI is ordered.

Development of PET Methodology for Monitoring Early Responses to Chemotherapy in Breast Cancer Patients
Carla Molthoff, Ph.D.
VU University Medical Center

Lesion Discrimination in Young Women by Functional Optical Tomography
Christoph Schmitz, Ph.D.
The Research Foundation of SUNY on behalf of SUNY Downstate Medical Center

The Role of TGF-β Signaling in Mammary Tumor Metastasis
Sponsor: Harold Moses, M.D.
Vanderbilt-Ingram Comprehensive Cancer Center

The Significance of the Epidermal Growth Factor Receptor and Cytochrome c Oxidase Subunit II Association in Breast Cancer: Implications in Mediating Cellular Survival
Sponsor: Sarah Parsons, Ph.D.
University of Virginia

Endocytosis and Signaling of the Epidermal Growth Factor: Role of Abi Tyrosine Kinases and Abi Adaptors
Sponsor: Ann Marie Pendergast, Ph.D.
Duke University

The Role of Altered Huntingtin Interacting Protein 1 (HIP1) Levels in the Biology of Breast Cancer
Sponsor: Theodora Ross, M.D.
University of Michigan

Characterization of Effects of MUC1 Overexpression on Epidermal Growth Factor Receptor Signaling
Sponsor: Joyce Schroeder, Ph.D.
University of Arizona

P53-Dependent Dysregulation of IL-6/raft/STAT3 Signaling in Breast Cancer
Sponsor: Pravin Sehgal, M.D.
New York Medical College

Heterochromatin Protein 1: Development of a Novel Breast Cancer Metastasis Marker
Sponsor: Lori Wallrath,
University of Iowa

HoxA9, the Tumor Suppressors BRCA1 and PTEN and Breast Cancer
Sponsor: Valerie Marie Weaver, Ph.D.
University of Pennsylvania

Maintenance of Genome Stability and Telomere Length by Pfh1p DNA Helicase in Schizosaccharomyces Pombe
Sponsor: Virginia Zakian, Ph.D.
Princeton University
The Interdisciplinary Breast Fellowship Program is designed to improve the quality of care for breast cancer patients. In 1998, the Komen Foundation developed a pilot program for interdisciplinary fellowship training in partnership with the University of Texas Southwestern Medical Center (UTSW). With the successful implementation of the UTSW pilot program and subsequent collaborations with the American Society of Breast Diseases, American Society of Breast Surgeons and the Society of Surgical Oncology, the Komen Foundation has developed a program for interdisciplinary fellowship training in breast care that will:

- Prepare highly motivated, talented and compassionate physicians for careers devoted to serving the multi-specialty needs of the breast cancer patient.
- Offer an interdisciplinary curriculum integrated into a comprehensive program.
- Provide special emphasis on enhancing the physician’s understanding of the patient with benign and malignant breast disease while developing a better treatment environment for future patients.
In addition to funding research and extensive community outreach programs, the Komen Foundation also supports a meritorious award program that includes the Brinker Award for Scientific Distinction and the Komen Professor of Survivorship Award.

2003 Brinker Award for Scientific Distinction
Established by the Komen Foundation in 1992, the Brinker Award for Scientific Distinction recognizes leading scientists for significant contributions that advance basic research concepts or clinical applications in the fields of breast cancer research, screening or treatment. The awardees are selected on a peer-review basis and are recognized each December during the annual San Antonio Breast Cancer Symposium.

Walter C. Willett, M.D., Dr. P.H., Clinical Research Award
Professor of Epidemiology and Nutrition and Chairman of the Department of Nutrition, Harvard School of Public Health; Professor of Medicine, Harvard Medical School

Dr. Willett, who is the author of a noteworthy book on the relationship between health and diet called Eat, Drink and Be Healthy: The Harvard Medical School Guide to Healthy Eating, was recognized for his exhaustive epidemiological studies of the links between dietary factors and health conditions, including breast cancer.

Mina J. Bissell, Ph.D., Basic Science Award
Distinguished Scientist, Life Sciences Division, Lawrence Berkeley National Laboratory

Dr. Bissell is a recognized leader in the field of cell and molecular biology. While studying the environment that surrounds breast cells in order to better understand breast cancer, Dr. Bissell attempts to unearth why, even though most tissues share the same genetic information, some tissues get cancer while others don’t.

2003 Komen Professor of Survivorship Award
Established in 1999 by the Komen Foundation and given annually, the Professor of Survivorship Award recognizes and rewards the efforts and achievements of individuals within the ranks of medicine, research, education and advocacy for their efforts to improve the overall quality of life for breast cancer survivors.

Noreen M. Aziz, M.D., Ph.D., M.P.H.
Program Director within the National Cancer Institute’s Office of Survivorship

Dr. Aziz was recognized for promoting efforts related to cancer survivorship and follow-up care as research priorities for the National Institutes of Health (NIH) in Bethesda, MD. Most recently, she coordinated a request for proposals for an initiative focusing on the concerns of long-term survivors. It netted more than 125 grant applications and was viewed as one of the most successful initiatives of its kind in NIH history.

Kathy S. Albain, M.D.
Clinical Director of the Breast Cancer Research Program, Co-Director of the Multidisciplinary Breast Oncology Center and Director of the Thoracic Oncology Program at Loyola’s Cardinal Bernardin Cancer Center in Chicago

Dr. Albain is involved in national research and advisory activities related to breast cancer, cancer survivorship and special populations. She chairs the Committee on Special Populations for the Southwest Oncology Group (SWOG). Under Dr. Albain’s leadership, an active lay advocate program was formed, enabling breast cancer survivors to participate in the development and implementation of SWOG protocols.
The Komen Foundation is dedicated to setting new standards for creative collaboration in the fight against breast cancer. And to that end, the Foundation develops outreach, awareness and fundraising initiatives with the dedication, commitment and support of numerous cause partners. These partnerships – with both corporations and organizations – provide an opportunity for individuals to join in the fight against breast cancer in a way that is meaningful to them. Whether it’s by purchasing and wearing a breast cancer awareness scarf designed by Lilly Pulitzer for Ford, or through participation in a local awareness and fundraising event like KitchenAid’s Cook for the Cure® or the BMW Ultimate Drive, our partners are making a real difference in the lives of millions. Three categories of partnership are highlighted on the pages that follow.

2003-2004 cause partners

- Belk Department Stores
- Breeder’s Choice
- Brinker International, Inc.
- Crest Uniforms
- Deluxe Corporation
- DSW
- Interiors by Decorating Den
- Lean Cuisine
- Loews Cineplex
- Ladies Professional Golf Association (LPGA)
- Masterfoods USA
- Napa Valley Trading Company
- Proflowers.com
- Republic of Tea
- Sherwin Williams
- Wacoal America
- Women’s National Basketball Association (WNBA)

million dollar council

The Komen Million Dollar Council is a special group of cause partners. In addition to a financial contribution of at least $1 million, each of these organizations has found new and innovative ways to spread two important messages: early detection saves lives and only though research can we find a cure. They are a tremendous help in the fight against breast cancer and we thank them for their generous commitment and support.

American Airlines began its partnership with the Komen Foundation in 1992 with an employee breast cancer education and awareness program. American Airlines is now the official airline carrier of the Foundation and is a National Series Sponsor of the Komen Race for the Cure®. American Airlines also hosts the annual American Airlines Celebrity Golf Weekend which benefits the Foundation.

BMW of North America, Inc. has partnered with the Komen Foundation through the BMW Ultimate Drive since 1997. The program features two cross country caravans of specially marked BMWs that guests are invited to test drive at BMW retail centers across the nation. For each mile driven, BMW contributes $1 to the Foundation. As of March 2004, BMW had donated $6 million to the Foundation for research and outreach programs.

Each year, the Carlisle Collection, Ltd. creates a special “Fabric of Hope” scarf to promote the Komen Foundation’s efforts in the fight against breast cancer. The scarf is a gift to anyone who makes a $125 or more donation to the Komen Foundation through a Carlisle consultant. Proceeds from the program have totaled more than $1 million through March 2004.
Ford Credit and NASCAR driver Dale Jarrett and his wife Kelley have been longtime supporters of the fight against breast cancer. In support of their partnership, Ford Credit makes a donation to the Foundation based on Dale Jarrett’s performance at NASCAR Nextel Cup events: $10,000 for each first place finish; $7,500 for each second; $5,000 for each third; and $5,000 for each pole position. Additionally, NASCAR fans can make contributions to the fight against breast cancer at Race Fans for the Cure trackside events.

Ford Division has served as a National Series Sponsor of the Komen Race for the Cure since 1994. In addition, Ford partners with designers to create a special breast cancer awareness scarf each year. Net proceeds from scarf sales (85% of each sale) are donated to the Foundation. On a grassroots level, Ford actively encourages involvement of its regional offices, local dealers and employees through volunteerism, monetary support, in-kind automotive services and local Race sponsorship. Ford is the exclusive automotive sponsor of the Komen Race for the Cure Series.

In 1999, Hallmark Gold Crown Stores launched Cards for the Cure, a program featuring a free, specially designed greeting card created by a Hallmark artist who is also a breast cancer survivor. All cards in the Cards for the Cure series feature a reminder of the importance of early detection. Each year, Hallmark also creates a special holiday Angel Ornament with $2 from each sale donated to the Foundation.

Johnson & Johnson Family of Consumer Companies has been a National Series Sponsor of the Komen Race for the Cure since 1998. In support of the Race Series, Johnson & Johnson encourages the public to participate in local Race events via an advertising, public relations and promotional campaign, including a nationwide Sunday newspaper insert reaching over 45 million people.

Since 1996, Kellogg Company has supported the Komen Race for the Cure Series and other programs. Driving awareness and support of the Komen Foundation’s mission is at the core of the Kellogg Company’s sponsorship and its “Keep the Promise” program. Kellogg relays breast health information as well as information about the Komen Race for the Cure to thousands of women through national retail and Komen Race activities.

Launched in 2001, Cook for the Cure raises funds for the Komen Foundation through the purchase of select KitchenAid products, special fundraising events, cooking classes and a grassroots program that helps supporters throw their own Cook for the Cure fundraising dinner parties. To date, Cook for the Cure has raised more than $2 million for the Komen Foundation and earned the 2003 Cause Marketing Forum’s prestigious Halo Award.

Since 1996, on one day in October, millions of Americans wear jeans in support of the fight against breast cancer. Companies, organizations and schools nationwide participate annually in Lee National Denim Day by encouraging employees, members, staff and students to wear denim in exchange for a $5 donation to the Komen Foundation.

Lee National Denim Day is the largest single day fundraiser for breast cancer research, education, screening and treatment. It is the most successful program of its kind – having raised more than $44 million through October 2003, with the Komen Foundation receiving 100 percent of all donations that are made. In addition to raising funds, the program also promotes breast cancer awareness and gives people who might not normally get involved in the cause a reason to do so.

Actress Christina Applegate served as the official celebrity spokesperson for the 2003 Lee National Denim Day. She joined the ranks of past Denim Day spokespersons like Lucy Liu and Rob Lowe in lending a voice to the cause by delivering vital messages about breast health, including the importance of early detection.

The Val Skinner Foundation was founded by Ladies Professional Golf Association (LPGA) Touring Professional Val Skinner, who has been dedicated to the fight against breast cancer since 1993 when close friend and fellow LPGA Player Heather Farr lost her battle to the disease at 28. Thanks to the LIFE Event (LPGA Pros In the Fight to Eradicate Breast Cancer), a premier golf event featuring current and past LPGA players, the Val Skinner Foundation has donated $1.25 million to the Komen Foundation for breast cancer research and outreach.
Mohawk Industries, Inc., is the manufacturer of Durkan Commercial, Karastan Contract and Durkan Patterned commercial carpets. When these products are specified by commercial interior designers, Mohawk donates $.25 per square yard sold in its commercial market to the Komen Foundation. Similarly, Mohawk Residential Flooring, manufacturer of brand name residential carpets, donates $.10 per yard to the Komen Foundation on select Mohawk residential carpet.

New Balance Athletic Shoe, Inc., has been associated with the Komen Race for the Cure® Series since 1989 and has served as a National Series Sponsor since 1991. Through its Lace Up for the Cure® program, for every postcard returned from a $25 or more New Balance Pink Ribbon Collection purchase, New Balance makes a $5 donation to the Komen Foundation up to $125,000. In addition, the company sponsors Honorary Team New Balance, a group of breast cancer survivors highlighted at Komen Races.

Occidental Chemical Corporation supports the Komen Foundation by providing office space at the Foundation's Headquarters in Dallas.

Since 1997, each October Pier 1 Imports, Inc., sells a commemorative Komen Candle with 25 percent of the purchase price from sales donated to the Foundation. Pier 1 has partnered with the Foundation since 1991. In 2003, Pier 1 donated nearly $200,000 to the Komen Foundation from the candle sales.

Rally For A Cure® is the first and largest national golf club program of its kind. Designed as a way to educate amateur female golfers about breast health and breast cancer, the program has also raised $12 million since 1996 through license fees and ancillary donations. These funds are donated to the Komen Foundation in support of research and outreach programs.

In its inaugural year, 356 Rally for a Cure® events were held throughout the United States. Due to the dedication and commitment of Rally Ambassadors, in 2003 nearly 3,000 events were held, reaching more than 145,000 participants.

A registration fee of $15 per person entitles Rally participants to enter a closest-to-the-pin or similar contest at a designated par-3 hole. In addition, everyone who participates receives a full-year subscription to Golf for Women Magazine, a pink ribbon pin and breast health education materials from the Komen Foundation.

2003 marks the third year of the Komen Foundation's partnership with RE/MAX International through its co-sponsorship of the Komen Race for the Cure® Series Breast Cancer Survivor Recognition Program. At each event, RE/MAX honors breast cancer survivors by providing signature pink t-shirts and caps for survivors to wear. Race participants also receive "In Memory of" or "In Celebration of" back signs to honor a friend or loved one. RE/MAX is the exclusive real estate sponsor of the Komen Race for the Cure® Series.

The Komen Foundation has received support from Titleist, Cobra and FootJoy Worldwide for nine years. These companies provide golfers with a distinctive reminder that early detection is an important key to survival by featuring the pink ribbon logo on Titleist and Pinnacle golf balls. In conjunction with Rally for a Cure®, sponsored by Golf For Women magazine, Titleist provides a pink ribbon custom-imprinted golf ball for every golfer who “hits the green.” This initiative reaches thousands of golfers worldwide.

In 2003, Ty Inc. debuted Cure™, a new member of its Beanie Baby family. The Pink Beanie Baby with a pink ribbon on its chest was sold nationwide by Ty retailers through March 2004. Ty made a $1 million donation to the Komen Foundation.

The Women's International Bowling Congress (WIBC) sponsors Bowl for the Cure®, a nationwide initiative designed to increase breast cancer awareness and raise funds for the Komen Foundation and the fight against breast cancer. The program has raised more than $3 million since it began. Participating bowling leagues designate a bowling session of their choice as a Bowl for the Cure® event and bowlers donate a “penny per pin” (or any amount they wish) during the designated session.

Beginning with the Women's Arctic Tour '93, and continuing with four national relays – Pony Express Tours '96, '98, 2000 and 2003 – the Women's Motorcyclist Foundation, Inc. (WMF) hosts motorcycle-riding campaigns to raise money for the Komen Foundation to support the fight against breast cancer. The Komen Foundation has received more than $1 million from Pony Express riders.
**Wyndham Hotels & Resorts** is the National Hotel Partner of the Foundation. In 1999, Wyndham began observing National Breast Cancer Awareness Month with its Dream for the Cure® program to help support breast cancer research, education, screening and treatment. Through Dream for the Cure®, guests receive specially designed pillow cards in their room, and are provided an opportunity to make a donation directly to the Komen Foundation. Wyndham also provides valuable in-kind support through use of guest rooms for Foundation business.

**Yoplait USA** has served as National Presenting Sponsor of the Komen Race for the Cure® series since 2001. Yoplait was a National Series Sponsor of the Komen Race for the Cure® in 2000 and served as the National Volunteer Program Sponsor of the Race Series in 1999. In addition to supporting the Race Series, Yoplait sponsors the highly successful Save Lids to Save Lives” program, which takes place throughout September and October each year. For each pink lid mailed in by customers, Yoplait donates 10 cents to the Komen Foundation (up to $1.2 million).

**Zeta Tau Alpha (ZTA)** became the first sponsor of the Breast Cancer Survivor Recognition Program at Komen Race for the Cure® events in 1992. As part of its co-sponsorship, ZTA provides “In Memory of” and “In Honor of” back signs to Race participants and pink hats and t-shirts to breast cancer survivors. Additionally, Zetas have distributed more than nine million Breast Self-Examination cards, 3.3 million Breast Self-Examination calendar reminder stickers and 1.25 million THINK PINK!® ribbons and information cards.

**komen race for the cure® series sponsors**
The Komen Race for the Cure® Series is privileged to have the generous support of nine major corporations and one of the nation’s largest fraternal organizations. Each Race Series Sponsor provides a cash commitment to cover a large portion of the expenses associated with hosting a national series of more than 100 Race events. Just a few of the expenses they help cover include Race T-shirts for all participants, survivors and volunteers, and national advertising. In addition, each sponsor develops and implements programs, promotions and activities to support Races in their local communities. Examples include airline tickets, gift certificates, local advertising, local fundraising support, product samples and special product sales.

**National Presenting Sponsor**
- Yoplait

**National Series Sponsors**
- American Airlines
- Ford
- Johnson & Johnson Family of Consumer Companies
- Kellogg’s
- New Balance
- Quilted Northern Ultra®
- Silk Soymilk

**Breast Cancer Survivor Recognition Program**
- RE/MAX
- Zeta Tau Alpha Fraternity
Norman Brinker
Mr. Brinker is chairman emeritus of Brinker International, a restaurant group that includes Chili’s Grill & Bar and Romano’s Macaroni Grill, among others. Mr. Brinker began his career in the restaurant industry in 1957 with Jack-In-The-Box. He established Steak and Ale restaurants in 1965. Steak and Ale merged with Pillsbury in 1976, and in 1982, he became president of the Pillsbury Restaurant Group, overseeing such restaurants as Steak and Ale, Burger King and Bennigan’s. In 1983, he invested in and became chairman and CEO of Chili’s, Inc., now known as Brinker International. He has served on the Foundation Board since its inception in 1982.

Linda Custard
Ms. Custard is a full-time volunteer with a wide range of experience in educational, cultural and social service boards. She has served as president of the Junior League of Dallas, vice chair of the United Way of Metropolitan Dallas, chair of the Board of Trustees of the Hockaday School, president of the Community Council of Greater Dallas and president of the Dallas Woman’s Club. Presently, she serves as a Trustee of Southern Methodist University and as a Director of the Dallas Center for the Performing Arts Foundation.

LaSalle D. Leffall, Jr., M.D. – Chairman of the Board
Dr. Leffall is the Charles R. Drew Professor of Surgery at the Howard University College of Medicine. He is a surgeon, oncologist, medical educator and leader in professional and civic organizations. In May 2002, Dr. Leffall was appointed by President George W. Bush as a member and chair of the President’s Cancer Panel. He graduated summa cum laude from Florida A&M University with a B.S. degree in 1948. He received his M.D. from Howard University College of Medicine, ranking first in his class. He was an intern at Homer G. Phillips Hospital, St. Louis, MO; assistant resident and chief resident in surgery at Freedmen’s Hospital, Washington, D.C.; and senior fellow in cancer surgery, Memorial Sloan-Kettering Cancer Center, New York, NY. Dr. Leffall began his military career at the rank of Captain, M.C., serving as Chief of General Surgery, U.S. Army Hospital, Munich, Germany, 1960-61. He joined the faculty at Howard University in 1962 as assistant professor. He continued with appointments as acting dean and professor. He became chairman of the department of surgery in 1970, a position he held for 25 years.

Connie O’Neill
Ms. O’Neill has been involved with the Komen Foundation since 1992, serving as treasurer for two years previously and chairing the National Awards Luncheon in 1994. In 2000, she was again appointed treasurer of the Komen Foundation and will serve as Foundation treasurer for three years. Ms. O’Neill also serves on the boards of Children’s Health Services of Texas, Children’s Medical Center Foundation and Presbyterian Healthcare Foundation. She is a member of the Leadership Dallas Alumni Association and the Crystal Charity Ball. She was formerly president of the Junior League of Dallas and has also served on the boards of the United Way of Metropolitan Dallas, St. Paul Medical Center Foundation and the Southern Methodist University Alumni Association. Ms. O’Neill is a 1977 graduate of SMU and worked as a certified public accountant for Ernst & Young from 1977 to 1985.
2003-2004 board of directors

Lynn Sellers
Ms. Sellers is a past Komen Race for the Cure® chair and long-time volunteer with the Komen Charleston Affiliate. She was instrumental in forming the Komen Charleston Affiliate’s board in 1999, served as the survivor luncheon chair in 2000-2001 and was honored as the local hero for the BMW Ultimate Drive in 2001. She currently serves as a member of the Foundation’s Volunteer Advisory Council. Ms. Sellers earned a B.S. in Economics from the College of Charleston.

Neel Stallings
Ms. Stallings, Affiliate representative to the Komen Board of Directors, began volunteering with the Komen Charlotte Affiliate in 1997 following her sister’s breast cancer diagnosis. In 1997 she helped launch the first Komen Charlotte Race for the Cure® and in 1999 she co-chaired the event. Six weeks after stepping up to this position, Ms. Stallings received her own breast cancer diagnosis. A five-year survivor, Ms. Stallings has served as a member of the Komen Charlotte Affiliate’s Board of Directors since it began in November 1999 and served as Chair, Education/Community Outreach Committee, from 2000-2003. She was also a member of the Komen Foundation’s National Volunteer Advisory Council from 2002-2004. A human resources learning strategist in Charlotte, she is a project manager and faciliator for leadership development, customer service excellence and distributive learning for Wachovia Bank.

Robert Taylor
Mr. Taylor is general counsel at Taylor Lohmeyer Corrigan, P.C. He also serves as chairman of the Dallas/Fort Worth Duke University Alumni Admissions Committee and is past chairman of the Highland Park United Methodist Church Board of Trustees. Mr. Taylor received his A.B. and J.D. from Duke University and received his L.L.M. and S.J.D. in Taxation from Georgetown Law Center.

Stephen W. Wyatt, D.M.D., M.P.H.
Dr. Wyatt is dean of the University of Kentucky College of Public Health and associate director for Cancer Control, University of Kentucky Markey Cancer Center. He attended Murray State University and earned a Doctor of Dental Medicine degree in 1980 from the University of Kentucky. He attended the University of Alabama-Birmingham (1984-1985) and went on to earn his master’s degree in public health from the University of Illinois in Chicago in 1986. He attended the Public Health Leadership Institute at San Diego State University (1993-1994). From 1980 to 2000, Wyatt served as an officer in the U.S. Public Health Service and retired as captain. From 1989 to 1998, he held several posts at the Centers for Disease Control, National Center for Chronic Disease Prevention and Health Promotion, including that of director for the CDC Division of Cancer Prevention and Control from 1995 to 1998. He currently serves as a member of Cancer in Rural Populations and the Cancer Center Advisory Committees at West Virginia University and the University of Alabama-Birmingham. Dr. Wyatt is a past recipient of the Komen Foundation’s Betty Ford Award.

Barney Young
Mr. Young is general counsel at Locke Liddell & Sapp LLP and has served on the Komen Board since 2000. Mr. Young also serves on the Board of Trustees for Friends of the Center for Human Nutrition, the Shelter Ministries of Dallas Foundation, the Dallas Historical Society and the National Association of Independent Schools. A magna cum laude graduate of Yale University, Mr. Young received his J.D. with honors from the University of Texas Law School.
Nancy Goodman Brinker

When Nancy Brinker’s sister, Suzy, died of breast cancer at the age of 36 in 1980, Nancy promised herself that she would fulfill her sister’s plea to help others battling the disease. In 1982, she established the Susan G. Komen Breast Cancer Foundation, today recognized as the nation’s leading catalyst in the fight against breast cancer. Ms. Brinker also founded the Komen Foundation’s signature program — the Komen Race for the Cure®, the largest series of 5K run/fitness walks in the world. Since its origin in 1983 in Dallas, Texas, the Race Series has grown from one local Race with 800 participants to a national series of more than 100 Races and more than one million participants.

In 2001, President Bush appointed Ms. Brinker to serve as U.S. Ambassador to the Republic of Hungary. In 1986, President Reagan appointed Ms. Brinker to the 18-member National Cancer Advisory Board as one of six laypeople. In 1992, she was appointed by President Bush to the three-member President’s Cancer Panel to monitor the progress of the National Cancer Program and was selected by Vice President Quayle to serve as the chairman of a subcommittee to study the progress of breast cancer research and education in the United States and around the world. Prior to assuming her position as Ambassador, she served on numerous boards and advisory councils. She has received numerous national awards including, most recently, the 2004 Service to America Leadership Award presented by the National Association of Broadcasters Educational Foundation.

2003-2004 staff leadership

Susan Braun
President and Chief Executive Officer

Rebecca Garcia, Ph.D.
Vice President, Health Sciences

Patrice Tosi
Chief Operating Officer, Executive Vice President

Andrew Halpern
Vice President, General Counsel

Nancy Byrd
Vice President, Domestic Affiliate Network

Cindy Schneible
Vice President, Cause Related Marketing
For more than 20 years, the Komen Foundation has been in the business of doing good, working to create a world without breast cancer. It’s our guiding passion. And while we’re passionate about our goal, we know that to reach it we must also be a strong business. And we operate accordingly.

As a non-profit organization, we’re often faced with the preconceived notion that by strongly supporting our mission, we might not operate as efficiently as a for-profit business. At the Komen Foundation, this summation could not be further from the truth. Because we fund some of the world’s most promising breast cancer research and innovative community outreach programs, it’s imperative that we adhere to a firm set of operating principles similar to those practiced by successful for-profit companies. If we want to continue to provide help to those suffering from breast cancer today and hope for an ultimate end to the disease tomorrow, we must be smart about our money – the way we raise it and the way we spend it.

A strong example comes from our cause marketing programs. We utilize standard business contracts with clear terms that protect us and our potential corporate partner. Most importantly, these contracts protect and fully inform the consumer, the person who’s making a contribution to the fight against breast cancer through his or her purchases or participation in an event or program. Further, when selecting our partners, we have extremely high standards and work to ensure there is a sincere commitment to the fight against breast cancer that corresponds with our mission and core values.

At the Komen Foundation, we spend the dollars entrusted in our care through donations and fundraising events and programs the same way we raise them – with a clean, business-like approach. For instance, in the area of research, our blind, peer-review process helps us sustain a “level playing field.” Grant applications are evaluated based upon their merit and potential outcomes – not on the scientist or his institution. At the local level, all grants are awarded based upon a community needs assessment. This process helps avoid duplication and guides us in funding critically needed programs and services.

By placing staff strategically and running a lean operation that relies heavily upon a network of dedicated volunteers, we have built a sturdy infrastructure that frees up our dollars and our people so that we can focus on the real issue at hand: ending breast cancer. Our business model allows us to translate our passion into effective action.

And that action has a single focus – to end breast cancer. It is always at the very heart of what we do. Everyone who is a part of the Komen Foundation has been touched by breast cancer in some way. We feel the pain it causes and we honor the lives lost. We are driven by an urgency that comes from the fact that in the United States we still lose more than 100 people every day to this disease.

We firmly believe there is no choice when it comes to the business of doing good. We will operate efficiently, raise money well, spend it well and target the right goal. And we will continue down this path in order to reach our ultimate goal – a world without breast cancer.

Susan Braun
President and Chief Executive Officer
our mission

The mission of the Susan G. Komen Breast Cancer Foundation is to eradicate breast cancer as a life-threatening disease by advancing research, education, screening and treatment.

our guiding principles were born from a simple promise made between two sisters.

- We believe in the power of the individual – recognizing the extreme value of one and the dynamic force of many.

- We honor voluntarism and foster the spirit to serve by the lives that we touch.

- We nurture an environment where people are valued and treated with dignity, respect and fairness.

- We are committed to being a positive agent of change – demonstrating compassion and integrity in all that we do.

- We believe that distinguished financial performance is a must, not as an end in itself, but as a means to accomplish our broader mission.